1. Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. Issue 12 (December 2013) Authors: Brander, Danielle; Rizzieri, David; Gockerman, Jon; Diehl, Louis; Shea, Thomas Charles; Decastro, Carlos; Moore, Joseph O.; Beaven, Anne Journal: Leukemia & lymphoma Issue: Volume 54:Issue 12(2013:Dec.) Page Start: 2627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗